Hospital Beata Maria Ana

Madrid 73 trials 41 recruiting

73 Registered trials

41 Currently recruiting

Organisation

Hospital Beata Maria Ana

Location

Madrid, Spain

Identifier

ORG-100048975

Address

Calle Del Doctor Esquerdo No. 83, 28007, Spain

Departments

#034003 Oncology
#03403 :Oncología medica
Hematology
IOB Madrid Institute of Oncology
Medical Oncology
Medical Oncology Department
N/A
Oncología
Oncologia Medica
Oncology
Oncology Department
Servicio de Oncologia
Servicio de Oncología Médica
Unidad de Cáncer de Mama
Unidad Oncologica Medica

Clinical trials at this site (73)

Search interface

An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting

2024-519913-76-00 PDL1-negative metastatic triple-negative breast cancer 4 2025-12-09
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting

2024-517261-16-00 Advanced solid tumors 9 2025-12-05
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
Dose Escalation and Dose Expansion Study of BBO-10203 in Subjects with Advanced Solid Tumors Recruiting

2024-519445-29-00 Solid Tumors 1 2025-10-02
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun… Recruiting

2023-506539-14-00 Oncology 3 2025-05-27
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting

2023-508112-35-00 ROS1-positive non-small cell lung cancer (NSCLC) with a 4 2025-04-15
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizum… Recruiting

2023-503675-24-00 Triple-negative Breast Cancer 5 2025-01-17
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting

2024-512161-14-00 Breast Cancer 3 2025-01-14
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting

2023-508435-31-00 Advanced Solid Tumors, Advanced Breast Cancer 1 2024-08-09
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended

2024-517868-33-00 NECTIN4 Amplified Advanced Breast Cancer 4 2025-06-12
"Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)… Ended

2024-513511-27-00 HR-negative/HER2-negative resectable stage I TNBC. 4 2025-05-29
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16